Get the Stockscreener App
13.94
0.14%
-0.02
Pre-market:
13.92
-0.02
-0.14%
Ventyx Biosciences Inc stock is traded at $13.94, with a volume of 913.77K.
It is down -0.14% in the last 24 hours and up +0.94% over the past month.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
See More
Previous Close:
$13.96
Open:
$13.95
24h Volume:
913.77K
Relative Volume:
0.31
Market Cap:
$1.00B
Revenue:
-
Net Income/Loss:
$-192.96M
P/E Ratio:
-4.2242
EPS:
-3.3
Net Cash Flow:
$-167.04M
1W Performance:
+0.22%
1M Performance:
+0.94%
6M Performance:
+428.03%
1Y Performance:
+760.49%
1-Day Range:
$13.94
$13.96
1-Week Range:
$13.89
$13.97
52-Week Range:
$0.783
$25.00
Ventyx Biosciences Inc Stock (VTYX) Company Profile
Name
Ventyx Biosciences Inc
Sector
Industry
Phone
(760) 407-6511
Address
12790 EL CAMINO REAL, SUITE 200, SAN DIEGO
Compare VTYX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTYX
Ventyx Biosciences Inc
|
13.94 | 1.00B | 0 | -192.96M | -167.04M | -3.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.24 | 117.59B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
778.97 | 79.81B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
834.55 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.28 | 42.67B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
351.27 | 39.11B | 4.98B | 69.60M | 525.67M | 0.5198 |
Ventyx Biosciences Inc Stock (VTYX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-12-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Mar-12-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-07-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-07-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-07-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-07-23 | Downgrade | Stifel | Buy → Hold |
| Nov-07-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Mar-21-23 | Initiated | Wells Fargo | Overweight |
| Dec-19-22 | Initiated | Goldman | Buy |
| Nov-17-22 | Initiated | Morgan Stanley | Overweight |
| Sep-07-22 | Initiated | Stifel | Buy |
| Sep-01-22 | Initiated | H.C. Wainwright | Buy |
| May-09-22 | Initiated | Credit Suisse | Outperform |
| Mar-31-22 | Initiated | Canaccord Genuity | Buy |
| Feb-01-22 | Initiated | Oppenheimer | Outperform |
| Nov-15-21 | Initiated | Jefferies | Buy |
| Nov-15-21 | Initiated | Piper Sandler | Overweight |
View All
Ventyx Biosciences Inc Stock (VTYX) Latest News
Halper Sadeh LLC is Investigating Whether VAL, STKL, VTYX are Obtaining Fair Deals for their Shareholders - GlobeNewswire
Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investi - The National Law Review
Panic Selling: Does Ventyx Biosciences Inc have a sustainable dividendForecast Cut & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ventyx Biosciences, Inc.VTYX - Business Wire
Halper Sadeh LLC Encourages STEL, GORO, SKYT, VTYX Shareholders to Contact the Firm to Discuss Their Rights - InsideNoVa.com
SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--SKYT, GORO, STEL, and VTYX - Benzinga
Does Ventyx Biosciences Inc offer margin of safetyWeekly Profit Report & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Lilly-Ventyx US premerger waiting period set to expire Feb. 23 - MLex
Ventyx Biosciences Sets March 3, 2026 Vote on Eli Lilly $14-Per-Share Cash Merger - TipRanks
Aug Movers: Is QMCO stock a hidden gemEarnings Performance Report & Stepwise Trade Signal Implementation - baoquankhu1.vn
Chipmakers Recap: Does Ventyx Biosciences Inc meet Warren Buffetts criteriaJuly 2025 Technicals & Growth Focused Entry Reports - baoquankhu1.vn
Short Interest in Ventyx Biosciences, Inc. (NASDAQ:VTYX) Drops By 37.7% - MarketBeat
Will Ventyx Biosciences Inc. benefit from rate cutsEarnings Beat & Daily Price Action Insights - mfd.ru
Halper Sadeh LLC Encourages NATH, VTYX, SKYT Shareholders to Contact the Firm to Discuss Their Rights - marketscreener.com
Assessing Ventyx Biosciences (VTYX) Valuation After Sharp Share Price Momentum And A High P/B Multiple - Yahoo Finance
Ventyx Biosciences (VTYX) Price Target Increased by 12.94% to 13.99 - MSN
Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Invest - GuruFocus
SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger—VTYX, ALEX, RVYL, and FFWM - morningstar.com
Ventyx Biosciences approves cash bonus awards for executives ahead of planned merger - Investing.com Nigeria
Ventyx Biosciences approves cash bonus awards for executives ahead of planned merger By Investing.com - Investing.com South Africa
Ventyx Biosciences Sets Special Cash Bonuses Amid Lilly Merger - TipRanks
Institution Moves: Is Ventyx Biosciences Inc forming a double bottomQuarterly Portfolio Summary & Safe Entry Trade Reports - baoquankhu1.vn
Aug Update: Can Caledonia Mining Corporation Plc be the next market leaderMarket Rally & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Does Ventyx Biosciences Inc. meet Warren Buffett’s criteria2025 Trade Ideas & Expert Curated Trade Setups - baoquankhu1.vn
Halper Sadeh Investigates Ventyx and Sun Country Transactions - Intellectia AI
Market Fear: Will Ventyx Biosciences Inc stock hit new highs in YEAR2025 Support & Resistance & Reliable Intraday Trade Plans - baoquankhu1.vn
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Nathan’s Famous, Inc. (Nasdaq – NATH), Lisata Therapeutics, Inc. (Nasdaq – LSTA), Sun Country Airlines Holdings, Inc. (NasdaqSNCY), Ventyx Biosciences, Inc. (Nasdaq - GlobeNewswire Inc.
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Given Average Recommendation of "Reduce" by Analysts - MarketBeat
Published on: 2026-01-21 17:52:30 - baoquankhu1.vn
Does Ventyx Biosciences Inc. stock reflect fundamentalsPortfolio Return Summary & Weekly Top Stock Performers List - bollywoodhelpline.com
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Short Interest Update - MarketBeat
Will Ventyx Biosciences Inc. stock split attract more investorsMarket Sentiment Summary & Entry Point Confirmation Alerts - bollywoodhelpline.com
Eli Lilly Acquires Ventyx Biosciences for $1.2 Billion, Strategizing Beyond Weight Management Drugs - Intellectia AI
Could Acquiring Ventyx Biosciences Send Eli Lilly Stock Soaring in 2026? - Finviz
Halper Sadeh Investigates ON24, Ventyx, and Sun Country for Potential Violations - Intellectia AI
Risk Off: Can RAPT Therapeutics Inc benefit from deglobalizationJuly 2025 Spike Watch & Stepwise Swing Trade Plans - baoquankhu1.vn
Analyst Calls: Will Ventyx Biosciences Inc stock hit new highs in YEARQuarterly Portfolio Summary & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Eli Lilly Acquires Ventyx Biosciences for $1.2 Billion, Expanding Drug Pipeline - Intellectia AI
Citizens Financial Group Inc. RI Takes Position in Ventyx Biosciences, Inc. $VTYX - MarketBeat
Eli Lilly Stock Rallies as Ventyx Deal Calms Wegovy Concerns - MarketBeat
Eli Lilly’s $1.2 Billion Acquisition of Ventyx Biosciences: Bridging the Gap Between Weight Loss and Chronic Inflammation - FinancialContent
Aug Sectors: What are Ventyx Biosciences Incs earnings expectationsWall Street Watch & Free Long-Term Investment Growth Plans - baoquankhu1.vn
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ventyx Biosciences, Inc.VTYX - yourwyominglink.com
Daily Breeze - FinancialContent
Halper Sadeh LLC Encourages VTYX, SNCY, EKSO Shareholders to Contact the Firm to Discuss Their Rights - marketscreener.com
Halper Sadeh LLC Encourages VTYX, FONR, SNCY, FFIC Shareholders to Contact the Firm to Discuss Their Rights - marketscreener.com
Upcoming Events - FinancialContent
Ventyx Biosciences Inc Stock (VTYX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.09%
2.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):